Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Hazenberg, Mette D  [Clear All Filters]
Journal Article
J Munneke M, Björklund AT, Mjösberg JM, Garming-Legert K, Bernink JH, Blom B, Huisman C, van Oers MHJ, Spits H, Malmberg K-J, et al. Activated innate lymphoid cells are associated with a reduced susceptibility to graft versus host disease. Blood. 2014.
van Lier YF, de Bree GJ, Jonkers RE, Roelofs JJTH, Berge IJMTen, Rutten CE, Nur E, Kuijpers TW, Hazenberg MD, Zeerleder SS. Allogeneic hematopoietic cell transplantation in the management of GATA2 deficiency and pulmonary alveolar proteinosis. Clin Immunol. 2020:108522.
Hazenberg MD, Haverkate NJE, van Lier YF, Spits H, Krabbendam L, Bemelman WA, Buskens CJ, Blom B, Shikhagaie MM. Human ectoenzyme-expressing ILC3: immunosuppressive innate cells that are depleted in graft-versus-host disease. Blood Adv. 2019;3(22):3650-3660.
Garrido HMGarcia, Haggenburg S, Schoordijk MCE, Meijer E, Tanck MWT, Hazenberg MD, Rutten CE, de Bree GJ, Nur E, Meek B, et al. Immunogenicity of a 5-dose pneumococcal vaccination schedule following allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2022.
Broers AEC, de Jong CN, Bakunina K, Hazenberg MD, Kooy Mvan Marwij, de Groot M, van Gelder M, Kuball J, van der Holt B, Meijer E, et al. Posttransplant Cyclophosphamide for Prevention of Graft-versus-Host Disease: The Prospective Randomized HOVON-96 Trial. Blood Adv. 2022.
J Munneke M, Spruit MJA, Cornelissen AS, van Hoeven V, Voermans C, Hazenberg MD. The Potential of Mesenchymal Stromal Cells as Treatment for Severe Steroid-Refractory Acute Graft-Versus-Host Disease: A Critical Review of the Literature. Transplantation. 2015.
de Jong G, Janssen JJWM, Biemond BJ, Zeerleder SS, Ossenkoppele GJ, Visser O, Nur E, Meijer E, Hazenberg MD. Survival of early post-hematopoietic stem cell transplantation relapse of myeloid malignancies. Eur J Haematol. 2019.